advanced search
Experic_ONdrugDelivery_InhalationAd_728x90

EXPERT VIEW

CAPSULES FOR DRY POWDER INHALATION – A COMPLETE PRODUCT
EXPERT VIEW
Anita Solanki
CAPSULES FOR DRY POWDER INHALATION – A COMPLETE PRODUCT
Anita Solanki, Jnanadeva Bhat and Justin Kalafat discuss capsules for dry powder formulation and consider their potential as a dosage form for patients with respiratory conditions and systemic illnesses.
WHY GENE THERAPY IS PERFECT FOR TREATING OCULAR DISEASES
EXPERT VIEW
Dr Yongdong Zhou
WHY GENE THERAPY IS PERFECT FOR TREATING OCULAR DISEASES
Yongdong Zhou discusses the applications, advantages and challenges of gene therapy in the ophthalmic sector.
ENVISIONING NEW HORIZONS IN OCULAR DRUG DELIVERY
EXPERT VIEW
Dr Jay S Duker
ENVISIONING NEW HORIZONS IN OCULAR DRUG DELIVERY
Jay S Duker discusses the history and future of ocular drug delivery, with a special focus on posterior segment diseases and the battle to overcome significant patient and caregiver burdens.
KEEPING UP WITH THE DEMAND FOR EFFECTIVE OPHTHALMIC DRUGS
EXPERT VIEW
Robert Lee
KEEPING UP WITH THE DEMAND FOR EFFECTIVE OPHTHALMIC DRUGS
Robert Lee explores the growth of the ophthalmic drug market and discuss the challenges that pharma companies may face when creating drugs to treat some of the most common ocular indications.
A VIEW ON THE USE OF APROTIC SOLVENTS IN PARENTERAL DRUG FORMULATIONS
EXPERT VIEW
Michael Neely
A VIEW ON THE USE OF APROTIC SOLVENTS IN PARENTERAL DRUG FORMULATIONS
Michael Neely presents a review and discussion of the status of aprotic solvents as a solubilising vehicle for parenteral drug formulations in the context of the industry’s increasing interest in biologic drugs.
DRUG DELIVERY DEVICE TRENDS FOR 2022
EXPERT VIEW
Tom Oakley
DRUG DELIVERY DEVICE TRENDS FOR 2022
Tom Oakley looks at some of the current trends in the drug delivery industry and projects some of the key factors that will influence drug delivery decision making in 2022.
VOICE-ACTIVATED USER INTERFACES IN DRUG DELIVERY DEVICES CAN ENHANCE COMPLIANCE AND OUTCOMES
EXPERT VIEW
Salvatore Forte
VOICE-ACTIVATED USER INTERFACES IN DRUG DELIVERY DEVICES CAN ENHANCE COMPLIANCE AND OUTCOMES
Salvatore Forte looks at the evolution of voice-activated interfaces in medical devices, particularly autoinjectors, and the advantages for patient compliance and quality of care.
MDR COMPLIANCE: PLANNING FOR POST-MARKET CLINICAL FOLLOW-UP
EXPERT VIEW
Dr Celeste Maksim
MDR COMPLIANCE: PLANNING FOR POST-MARKET CLINICAL FOLLOW-UP
Celeste Maksim discusses best practices for drug delivery device manufacturers when conducting post-market clinical follow-up activities, as mandated by the EU Medical Device Regulation.
EVOLVING ANALYTICAL METHODS: ADVANCES IN MOLECULE CHARACTERISATION
EXPERT VIEW
Eliza Lee
EVOLVING ANALYTICAL METHODS: ADVANCES IN MOLECULE CHARACTERISATION
Eliza Lee discusses some of the modern analytical techniques available for the characterisation of modern biologics, and how CDMOs equipped with these techniques are able to support pharmaceutical development.
“SOFTWARE AS A MEDICAL DEVICE” FROM A HUMAN FACTORS PERSPECTIVE
EXPERT VIEW
Natalie Shortt
“SOFTWARE AS A MEDICAL DEVICE” FROM A HUMAN FACTORS PERSPECTIVE
Natalie Shortt discusses the considerations and steps to take when planning usability engineering efforts for software as a medical device.
ADDRESSING THE CHALLENGES OF NASAL BIOTHERAPEUTIC DRUG DELIVERY
EXPERT VIEW
Robert Lee
ADDRESSING THE CHALLENGES OF NASAL BIOTHERAPEUTIC DRUG DELIVERY
Robert Lee discusses the benefits of administering drugs to the nasal cavity, as well as the main challenges in formulation for this route and the strategies that can be applied to overcome them.
POWDER CHARACTERISATION: A CRITICAL TOOL FOR THE EVOLUTION OF INHALED DRUG DELIVERY
EXPERT VIEW
Dr Joana Pinto
POWDER CHARACTERISATION: A CRITICAL TOOL FOR THE EVOLUTION OF INHALED DRUG DELIVERY
Jamie Clayton, Joana Pinto and Sarah Zellnitz discuss the benefits of multi-faceted powder characterisation in dry powder inhalation formulations and how it can support efforts to achieve net zero emissions.
SUSTAINABILITY, WASTE & REMANUFACTURING IN THE MEDICAL SECTOR
EXPERT VIEW
Cormac O'Prey
SUSTAINABILITY, WASTE & REMANUFACTURING IN THE MEDICAL SECTOR
Cormac O’Prey discusses some of the sustainability challenges facing the medical sector, such as how to make re-use and remanufacturing viable for high-volume, low-value products, and how answers can be found by looking to successful solutions deployed by other industries.
PHARMAPACK EUROPE DRUG DELIVERY AND PACKAGING ANNUAL SURVEY 2021
EXPERT VIEW
PHARMAPACK EUROPE DRUG DELIVERY AND PACKAGING ANNUAL SURVEY 2021
Pharmapack presents the results of its annual survey and market report, covering the latest Pharmapack Innovation Index and the inaugural Pharmapack Sustainability Index, and taking stock of where the survey results suggest the pharma industry currently is, and where it is heading, in terms of innovation and sustainability.
EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY
EXPERT VIEW
Charlie Dean
EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY
Charlie Dean, Kay Sinclair and Brennan Miles provide an overview of eight terms key to a common understanding in the ongoing, and crucial, discussion surrounding sustainability.
INTERVIEW WITH MATHIAS ROMACKER, EX-PFIZER, INJECTION DEVICES STRATEGY CONSULTANT
INTERVIEW
Mathias Romacker
INTERVIEW WITH MATHIAS ROMACKER, EX-PFIZER, INJECTION DEVICES STRATEGY CONSULTANT
In this exclusive interview, Mathias Romacker discusses a broad range of topics, from his professional expertise and history seeing the parenteral sector evolve first-hand, to his personal experience as a Crohn’s disease patient making use of the very devices he’s seen grow and develop.
USING SIMULATION AND MODELLING VERSUS PROTOTYPING FOR MEDICAL RADIO FREQUENCY DESIGN
EXPERT VIEW
Enrico Denna
USING SIMULATION AND MODELLING VERSUS PROTOTYPING FOR MEDICAL RADIO FREQUENCY DESIGN
Enrico Denna looks at the advantages of a simulation and modelling approach over prototyping for the design of medical products.
OPTIONS FOR ACTIVATION OF BATTERY-OPERATED MEDICAL DEVICES
EXPERT VIEW
Tim Resker
OPTIONS FOR ACTIVATION OF BATTERY-OPERATED MEDICAL DEVICES
Tim Resker looks at new technologies for powering on battery-operated drug delivery devices while considering battery drain, ingress protection and user-friendliness.
EXTENDING CONTAINER CLOSURE INTEGRITY TO WEARABLE INJECTORS
EXPERT VIEW
Shaun Devitt
EXTENDING CONTAINER CLOSURE INTEGRITY TO WEARABLE INJECTORS
Shaun Devitt looks at how the principles and methods of container closure integrity might be adapted for wearable injectors.
ARE VIRTUAL EVENTS A SUITABLE REPLACEMENT FOR FACE-TO-FACE EQUIVALENTS POST-PANDEMIC?
EXPERT VIEW
Mr Denis Marteau
Owen Mumford
ARE VIRTUAL EVENTS A SUITABLE REPLACEMENT FOR FACE-TO-FACE EQUIVALENTS POST-PANDEMIC?
Denis Marteau looks at the future of virtual industry events and conferences in a post-pandemic future.
INDUSTRIALISATION OF DRUG DELIVERY BEYOND MANUFACTURING
INDUSTRIALISATION
Napoleon Monroe
New Directions Technology Consulting
INDUSTRIALISATION OF DRUG DELIVERY BEYOND MANUFACTURING
Napoleon Monroe considers the impact of the changing technological landscape on how industrialisation in the healthcare industry is evolving, with reference to the idea of “patients as consumers” and how the relationship between consumers, information and industry has evolved in other sectors, such as tech and retail – and how big players in those sectors are looking to move into and disrupt healthcare.
AUTOMATED LIPID NANOPARTICLE PRODUCTION: FROM PROTOCOL DEVELOPMENT TO GMP MANUFACTURE
EXPERT VIEW
Richard Gray
AUTOMATED LIPID NANOPARTICLE PRODUCTION: FROM PROTOCOL DEVELOPMENT TO GMP MANUFACTURE
Richard Gray and Julia Rashba-Step discuss the benefits of automated lipid nanoparticle production.
OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY
EXPERT VIEW
Robert Lee
OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY
Robert Lee discusses the growth of the ocular drug delivery market, the challenges formulators face in developing novel ocular technologies, and the role contract development and manufacturing organisations have to play in this growing market segment.
ADDRESSING ONGOING AND NEW BIOAVAILABILITY CHALLENGES
EXPERT VIEW
Dr Stephanie Emory
ADDRESSING ONGOING AND NEW BIOAVAILABILITY CHALLENGES
Stephanie Emory explores the pros and cons of various technologies for enhancing solubility and bioavailability for oral drug formulations. Further, Dr Emory draws on her experience as a reviewer at the US FDA to discuss how developers can view the FDA as a partner to aid success when leveraging innovative approaches.
ANALYTICAL TECHNIQUES FOR THE FORMULATION OF GASTRORETENTIVE TABLETS
EXPERT VIEW
Jamie Clayton
ANALYTICAL TECHNIQUES FOR THE FORMULATION OF GASTRORETENTIVE TABLETS
Jamie Clayton, Phil Bone and Kyu Mok Hwang discuss the value of analyses such as mercury porosimetry and powder rheology in characterising excipients for gastroretentive tablet formulation, and go on to detail a case study investigating polymer excipients for a novel bilayer floating tablet.
THE POWER OF ONBOARDING: BUILDING PERSUASIVE USER EXPERIENCES FOR COMPANION APPS
EXPERT VIEW
Dr Ben Cox
THE POWER OF ONBOARDING: BUILDING PERSUASIVE USER EXPERIENCES FOR COMPANION APPS
Ben Cox discusses the value of onboarding in drug delivery device companion apps, and how it is a key component of converting a one-time user to a repeat user, unlocking the true value of companion apps as a tool for combating poor adherence to medications and gathering high-quality data.
ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
EXPERT VIEW
Dr Andrew Donnelly
ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
Andrew Donnelly and Shahid Uddin look at the challenges of self-administration of injectable viscous formulations and the technology that is helping to overcome these issues.
BIOCOMPATIBILITY OF MEDICINAL PRODUCT MEDICAL DEVICE COMBINATIONS FOR AIRWAY DELIVERY
EXPERT VIEW
Mark Turner
BIOCOMPATIBILITY OF MEDICINAL PRODUCT MEDICAL DEVICE COMBINATIONS FOR AIRWAY DELIVERY
Mark Turner discusses biocompatibility testing for inhaled medical products, with particular reference to ISO 18562, and what Medical Engineering Technologies has learned from three years of breathing component biocompatibility testing.
NASAL DELIVERY: AN OPPORTUNITY FOR SIGNIFICANT IMPROVEMENTS IN PATIENT CARE
EXPERT VIEW
Dr Stuart Madden
NASAL DELIVERY: AN OPPORTUNITY FOR SIGNIFICANT IMPROVEMENTS IN PATIENT CARE
Stuart Madden discusses the advantages of the nasal route of administration for the systemic delivery of therapeutics.
FORMULATION OPTIONS IN NASAL DRUG DELIVERY
EXPERT VIEW
Dr Richard Johnson
FORMULATION OPTIONS IN NASAL DRUG DELIVERY
Richard Johnson discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.
CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT
EXPERT VIEW
Robert Lee
CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT
Robert Lee discusses recent advances in ophthalmic dosage forms and how companies are meeting these challenges to better serve their customers.
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
EXPERT VIEW
Dr Suresh Gupta
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.
LINKING THE “D” & “M” IN CDMO
EXPERT VIEW
Mr John Ross
LINKING THE “D” & “M” IN CDMO
John Ross looks at the role of CDMOs in product development through to commercialisation and considers the benefits of consolidated “DM” models.
ROOM FOR INNOVATION?
EXPERT VIEW
Darren Mansell
ROOM FOR INNOVATION?
Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.
TOP FIVE DRUG DELIVERY TRENDS FOR 2021
EXPERT VIEW
Tom Oakley
TOP FIVE DRUG DELIVERY TRENDS FOR 2021
Tom Oakley provides an overview of the top five trends to expect in drug delivery in 2021.
TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY
EXPERT VIEW
Lars Skole
TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY
Lars Skole discusses emerging trends and challenges associated with growing parenteral packaging and labelling complexity – and how pharmaceutical developers and manufacturers can meet the challenges ahead.
Top